March 17, 2020 -- IDbyDNA and Illumina have partnered to bring next-generation sequencing (NGS) workflows to the global microbiology market to combat the COVID-19 pandemic. The companies will accelerate and improve testing for infectious diseases with NGS surveillance technology.
Under the terms of the agreement, the companies will co-market IDbyDNA's Explify platform for use with Illumina's NGS systems and library preparation. Together, the technologies will provide a streamlined workflow for infectious disease applications. In addition, IDbyDNA and Illumina will partner to codevelop research-use-only (RUO) workflows.
The partnership will enable broad distribution of NGS equipment and library prep, as well as high-fidelity NGS reagents and interpretation and reporting capabilities to laboratories and hospitals around the world.
The initial commercial RUO workflows derived from the partnership will focus on multiple infections, both routine and emerging public threats, for which pathogen identification and information regarding antimicrobial resistance markers can be improved with NGS techniques.
IDby DNA's Explify platform provides actionable insights that can be derived from NGS data. The companies believe that NGS-based testing in microbiology is the future of infectious disease testing and the combined technologies will provide the most comprehensive testing currently available.